Physician profile
Gordon E Pennebaker
NPI 1366494197
$4,510.08
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,212 · 2020: $1,509 · 2021: $1,697 · 2022: $12.58 · 2023: $79.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Gift: $79.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Gift | $79.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $440.87 | 2021-2023 | Sutab |
| Glaxosmithkline, LLC. | $425.80 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $414.15 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $323.01 | 2019-2021 | |
| Pfizer INC. | $265.18 | 2019-2021 | |
| Esperion Therapeutics, INC. | $250.23 | 2020-2021 | |
| Amgen INC. | $247.70 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.63 | 2019-2021 | |
| Novo Nordisk INC | $229.30 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $220.21 | 2019-2021 | |
| Amarin Pharma, INC. | $212.22 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $189.78 | 2019-2021 | |
| Abbvie INC. | $175.77 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $132.03 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $118.63 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $91.22 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $85.19 | 2019-2021 | |
| Astellas Pharma US INC | $83.94 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $62.63 | 2019-2021 | |
| Grifols USA, LLC | $46.48 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $35.96 | 2021 | |
| Bioventus LLC | $28.51 | 2019 | |
| Medtronic USA, INC. | $24.78 | 2019 | |
| Nestle Healthcare Nutrition INC. | $19.11 | 2021 | |
| Jazz Pharmaceuticals INC. | $18.87 | 2021 | |
| Acadia Pharmaceuticals INC | $17.96 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.58 | 2021 | |
| Boston Scientific Corporation | $13.60 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $13.50 | 2021 | |
| Medtronic Minimed, INC. | $13.34 | 2020 | |
| Sunovion Pharmaceuticals INC. | $12.90 | 2019 | |
| Mylan Specialty L.P. | $12.00 | 2019 | |
| Lilly USA, LLC | $11.75 | 2021 | |
| Seqirus USA INC | $11.64 | 2021 | |
| Eisai INC. | $11.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gordon Pennebaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.